TQB3728 / Sino Biopharm - LARVOL DELTA

Phase I study of TQB3728 tablets, an oral inhibitor of apoptosis proteins in patients with advanced solid tumor. (ASCO 2024) - P1 | "TQB3728 was well tolerated at doses up to 600mg but had limited anti-tumor activity in advanced solid tumor. According to the preliminary results, TQB3728 administered orally in combination with conventional chemo-radiotherapy is under exploration. Clinical trial information: NCT04523285."

Clinical • Metastases • P1 data • Anemia • Hematological Disorders • Oncology • Sleep Disorder • Solid Tumor

52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING (HKEXnews) - "The board of directors...of the Sino Biopharmaceutical Limited...announced that the Group’s category 1 innovative drugs...'TQB3617 (BET inhibitor)', 'TQB3728 (IAP antagonist)', 'TQB2930 (HER2 bispecific antibody)' and others will present 52 latest research results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, covering clinical research and basic research on multiple types of cancers..."

Clinical data • Breast Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Solid Tumor

To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. (clinicaltrials.gov) - P1/2 | N=78 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastases • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor